The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML.
Tran TH, et al. Among authors: braun bs.
Haematologica. 2021 Aug 1;106(8):2242-2245. doi: 10.3324/haematol.2020.261354.
Haematologica. 2021.
PMID: 33626861
Free PMC article.
No abstract available.